TMRW secures seed funding and partners with TruDiagnostic to bring deeper biological age testing to Australia’s growing longevity market.
Are we measuring age wrong? Your cells may already have the answer. That idea is quickly becoming one of the driving forces behind the longevity economy. As consumers grow more curious about how quickly their bodies are aging, a wave of startups has emerged, promising insights through blood testing and digital health dashboards.
But most of them, according to TMRW CEO Mark Britt, barely scratch the surface. While blood diagnostics have become the bread and butter of many health platforms, most simply deliver a PDF with a few dozen metrics and leave it at that. TMRW, by contrast, is building a much deeper picture of human health, one that analyzes around 1,700 biological data points to map how the body is aging over time.
Now investors are backing that vision. The Australia-based longevity platform has raised approximately $7 million in seed funding, with Sydney venture capital firm Tidal Ventures leading the round [1]. Melbourne-based Capital Zed also participated, alongside a group of high-net-worth entrepreneurs and family offices. Notably, many of these investors are also TMRW members themselves, a signal of how personal the longevity conversation has become.
The fresh capital will help the company expand its clinical footprint and improve the patient experience, moving beyond purely digital health tools and toward a more proactive healthcare model.
From dashboards to real-world care
Longevity startups have often leaned heavily on apps, dashboards and wearables. But TMRW is betting that the next phase of the industry will require something more tangible. Clinics, medical guidance and ongoing relationships with patients.
The new funding will allow the company to scale that hybrid model, blending advanced diagnostics with clinical support that helps people actually act on the data.
Britt says the company’s philosophy centers on building healthcare alongside its users, rather than simply broadcasting progress as a startup growth story.
“We’ve officially closed our $7m seed round led by Tidal Ventures and inked an exclusive Australian partnership with TruDiagnostic to bring world-leading epigenetic testing to our members,” Britt wrote in a recent post on LinkedIn.
Britt mentioned that it was a pleasure to speak with Bronwen Clune from Capital Brief regarding TMRW’s unique trajectory compared to other startups. She expressed her belief that the “building in public” trend is frequently driven by an entrepreneur’s ego; she noted that, instead, TMRW is committed to building alongside its patients as the company scales.
It’s a broader trend across the longevity field, in which we’re moving from passive tracking to active intervention.
A partnership built around biological age
Alongside the funding announcement, TMRW also revealed an exclusive Australian partnership with US-based diagnostics company TruDiagnostic.
The company specializes in epigenetic testing, a type of analysis that examines how lifestyle, environment and behavior influence the way genes function over time. This testing can estimate a person’s “biological age,” a measure of how quickly their body is aging compared with their chronological age.
The technology has already attracted high-profile users in the longevity world, including entrepreneur Bryan Johnson and celebrity Kim Kardashian.
For TMRW members, the partnership could open the door to a far more detailed understanding of their health trajectory and how daily choices may accelerate or slow the aging process.
Investors are paying attention
The seed round highlights a growing investor appetite for longevity platforms that combine data with clinical care.
Over the past few years, biological age testing has shifted from a niche research concept to a consumer-facing product category. However, many investors believe the real opportunity lies in turning those insights into long-term health strategies. In that sense, TMRW’s approach reflects a major evolution in the industry.
The first wave of health tech companies focused on tracking. Steps walked, heart rate monitored, sleep hours logged. The next wave is about interpretation and action: understanding what those signals actually mean for the body’s future.
As longevity science moves steadily from labs into everyday healthcare, platforms like TMRW are positioning themselves around data, medicine and prevention – where the real promise of longer, healthier lives may finally begin to take shape.
